Copyright Reports & Markets. All rights reserved.

Global Neuraminidase Inhibitors Drug Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Oseltamivir
    • 1.2.3 Zanamivir
    • 1.2.4 Peramivir
    • 1.2.5 Laninamivir
  • 1.3 Market by Application
    • 1.3.1 Global Neuraminidase Inhibitors Drug Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospital Pharmacy
    • 1.3.3 Retail Pharmacy
    • 1.3.4 Online Pharmacy
    • 1.3.5 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2015-2026)
  • 2.2 Global Neuraminidase Inhibitors Drug Growth Trends by Regions
    • 2.2.1 Neuraminidase Inhibitors Drug Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Neuraminidase Inhibitors Drug Historic Market Share by Regions (2015-2020)
    • 2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Neuraminidase Inhibitors Drug Players by Market Size
    • 3.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2015-2020)
    • 3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2015-2020)
  • 3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue
  • 3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio
    • 3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2019
  • 3.5 Key Players Neuraminidase Inhibitors Drug Area Served
  • 3.6 Key Players Neuraminidase Inhibitors Drug Product Solution and Service
  • 3.7 Date of Enter into Neuraminidase Inhibitors Drug Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Neuraminidase Inhibitors Drug Breakdown Data by Type (2015-2026)

  • 4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2015-2020)
  • 4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2021-2026)

5 Neuraminidase Inhibitors Drug Breakdown Data by Application (2015-2026)

  • 5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2015-2020)
  • 5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Neuraminidase Inhibitors Drug Market Size (2015-2026)
  • 6.2 North America Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
  • 6.3 North America Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
  • 6.4 North America Neuraminidase Inhibitors Drug Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Neuraminidase Inhibitors Drug Market Size (2015-2026)
  • 7.2 Europe Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
  • 7.3 Europe Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
  • 7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Neuraminidase Inhibitors Drug Market Size (2015-2026)
  • 8.2 China Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
  • 8.3 China Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
  • 8.4 China Neuraminidase Inhibitors Drug Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Neuraminidase Inhibitors Drug Market Size (2015-2026)
  • 9.2 Japan Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
  • 9.3 Japan Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
  • 9.4 Japan Neuraminidase Inhibitors Drug Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Neuraminidase Inhibitors Drug Market Size (2015-2026)
  • 10.2 Southeast Asia Neuraminidase Inhibitors Drug Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Neuraminidase Inhibitors Drug Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Neuraminidase Inhibitors Drug Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11Key Players Profiles

  • 11.1 Roche
    • 11.1.1 Roche Company Details
    • 11.1.2 Roche Business Overview
    • 11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
    • 11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2015-2020))
    • 11.1.5 Roche Recent Development
  • 11.2 GSK
    • 11.2.1 GSK Company Details
    • 11.2.2 GSK Business Overview
    • 11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
    • 11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2015-2020)
    • 11.2.5 GSK Recent Development
  • 11.3 Gilead Sciences
    • 11.3.1 Gilead Sciences Company Details
    • 11.3.2 Gilead Sciences Business Overview
    • 11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
    • 11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2015-2020)
    • 11.3.5 Gilead Sciences Recent Development
  • 11.4 Daiichi Sankyo
    • 11.4.1 Daiichi Sankyo Company Details
    • 11.4.2 Daiichi Sankyo Business Overview
    • 11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
    • 11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2015-2020)
    • 11.4.5 Daiichi Sankyo Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Neuraminidase Inhibitors Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuraminidase Inhibitors Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Oseltamivir
    Zanamivir
    Peramivir
    Laninamivir

    Market segment by Application, split into
    Hospital Pharmacy
    Retail Pharmacy
    Online Pharmacy
    Others

    Based on regional and country-level analysis, the Neuraminidase Inhibitors Drug market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Neuraminidase Inhibitors Drug market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Roche
    GSK
    Gilead Sciences
    Daiichi Sankyo
    Buy now